A novel scoring system for selecting the target patients of COVID-19 convalescent plasma therapy: A hypothesis - 24/06/21
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Abstract |
The primary cause of mortality in patients of coronavirus disease 2019 (COVID-19) is the cytokine storm and not directly due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Therefore, it is being stressed by transfusion medicine specialists to use COVID-19 convalescent plasma (CCP) therapy early in the course of the disease, preferably within 72 h of diagnosis. The authors herein, propose a scoring system for the rapid assessment of the patients who have tested positive for SARS-CoV-2. Therefore, a systematic approach may be followed and the patients can be categorised into two groups, namely, the low-risk group [LRG; score < 5] and the high-risk group [HRG; score ≥ 5] based on this scoring system. Those classified as an HRG should be administered CCP therapy within 72 h of a confirmed diagnosis of COVID-19 to neutralise the SARS-CoV-2 virus and prevent the occurrence of the cytokine storm. This in turn could help reduce the overall mortality in the recipients.
Le texte complet de cet article est disponible en PDF.Keywords : COVID-19, early convalescent plasma therapy, scoring system, disease severity, cytokine storm
Bienvenue sur EM-consulte, la référence des professionnels de santé.